Clinical Details of Cases With Karyotypic and FISH Results
| Case/UPN . | Diagnosis . | sCD3 . | Karyotype . | Metaphase YAC . | No. of Patients Interphase Signals . | No. Total of . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Location . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | Interphase . |
| . | . | . | . | . | . | . | . | . | . | . | Cells . |
| . | . | . | . | . | . | . | . | . | . | . | Examined . |
| T-ALL 103.3 | Myeloid/pre T-cell line | — | 46,XY,t(8; 14)(q24; q11),−9,der(12)t(12; 13)(p11; q11), −13,+2mar [10] | 14, (der14), der(8) | 4 | 11 | 79 | 4 | 2 | — | 109 |
| RPMI 8402 | T-cell line | αβ | 82∼89,XXX,add(4)(q35)×2,del(6)(q?)×2,−8, t(11; 14)(p15; q11)×2,−13×2,−15×2,−18,−22,+2-4mar [cp8] | 14, der(14), der(11) | — | — | — | — | — | — | — |
| Pre | T-ALL | +* | 46,XY,t(11; 14)(p13; q11)[14] | 14, der(14), der(11) | 5 | 63 | 32 | — | — | — | 201 |
| 258 | T-PLL | αβ | 46,XX[1]/44-45,XX,del(1)(q?),−2,add(5)(p?),−6, −7,−8,add(9)(p?),del(11)(q21),add(12)(p?),t(14; 14) (q11; q32),add(16)(q?),+mar1,+mar2×2 [cp8] | der(14+)¶, der(14q−)# | 9.5 | 54 | 30 | 5 | 1 | 0.5 | 190 |
| Bru | AT | — | 46,XY[3]/45,XY −14,der(14)t(14; 14)(q11;q32), inc[22]ρ | der(14q+)¶ | — | — | — | — | — | — | — |
| Deb | T-PLL | αβ | 46,XY[1]/42-45,XY,−2,−3,i(8)(q10),del(11)(q21),−12, inv(14)(q11q32),+3mar[cp18] | 14, inv(14)**, mar# | 4 | 77.5 | 18 | 0.5 | — | — | 249 |
| 231 | T-ALL | — | 46,XX [1]/46,XX,add(10)(q?),−14,+mar[3]/46,id,i(14)(q10)[5] | 14, add(10), mar# | 0.5 | 17 | 71 | 11 | 0.5 | — | 205 |
| Gam | AT | — | 46,XX [26]/46,XX,der(14) [6] | 14, der(14)¶ | — | — | — | — | — | — | — |
| HP-BALL | T-cell line | αβ | 89∼91,XX,t(1; 5)(q31; q34)×2,−3,−7,−8,−13, add(14)(q32)×2,−16×2,+mar1×2,+mar2×2 [cp6] | 4 × 14 | — | — | — | — | — | — | — |
| 572 | T-ALL | γδ | 46, XX,−5,add(14)(q32),+mar [20] | 2 × 14 | 7.5 | 89 | 2.5 | 1 | — | — | 200 |
| Peer | T-cell line | γδ | 86∼90,XXX,−4×2,−5,+6,del(6)(q?)×2,+7×2,−8×2, del(9)(p?)×2,+i(9)(p10)×2,−12,−13,−15,−18,+3-5 mar [cp9] | 4 × 14 | — | — | — | — | — | — | — |
| Molt13 | T-cell line | γδ | 46,XX,i(17)(q10)[10] | 2 × 14 | — | — | — | — | — | — | — |
| Molt4 | T-cell line | — | 96∼100,XXYY,+4,del(6)(q?)×2,+7,i(7)(q10)×2, +8,+9,−13,+3mar [cp6] | 4 × 14 | — | — | — | — | — | — | — |
| 639 | T-ALL/AML† | — | 84∼86,−11,del(11)(q23),−14×1∼3,+10mar,inc [20] | 3 × 14 | 3 | 29 | 61.5 | 6 | 0.5 | — | 201 |
| 957 | T-ALL | γδ | 46,XX[40]/47,XX,+8[4]∥ | 14, inv(14) | 4 | 88.5 | 7.5 | — | — | — | 200 |
| Sh | T-ALL | — | 46,XY[20] | 2 × 14 | 6.5 | 92 | 1.5 | — | — | — | 203 |
| 226 | T-ALL/AML* | — | 46,XY[18] | 2 × 14 | 9 | 89 | 1 | 1 | — | — | 173 |
| Lin | T-ALL | — | 46,XY[20] | 2 × 14 | 6.5 | 92.5 | 1 | — | — | — | 200 |
| 951 | T-ALL | αβ | 46,XX[65] | 2 × 14 | 6 | 86.5 | 5.5 | 2 | — | — | 207 |
| 872 | T-ALL | αβ | 46,XY[16] | 2 × 14 | — | — | — | — | — | — | — |
| 634 | T-ALL | — | 46,XY[21] | 14, inv(14) | — | — | — | — | — | — | — |
| 586 | T-ALL* | — ‡ | 46,XY[20] | der(14), der(10) | 6 | 93 | 1 | — | — | — | 204 |
| 282 | LGL-AL* | — | 46,XX[23] | 14, der(14), der(10) | 3 | 46.5 | 36.5 | 8 | 5 | 1 | 202 |
| Control means (n = 6) | 5.7 | 91.8 | 2.3 | 0.2 | — | — | 198 | ||||
| Control SD | 2 | 3.25 | 1 | — | — | — | — | ||||
| Abbreviation: UPN, unique patient number. | |||||||||||
| * See text for full immunophenotypic details. | |||||||||||
| † TCR αβ and γδ not assessed. | |||||||||||
| ‡ CD3 weak. | |||||||||||
| ρ Includes the analysis of mitoses containing other structural abnormalities. | ∥ Total number of metaphases examined in blood and bone marrow cultures. | ||||||||||
| ¶ Two signals observed at positions corresponding to bands 14q11 and 14q32. | |||||||||||
| # One signal observed at a position corresponding to band 14q11. | |||||||||||
| ** One signal observed at a position corresponding to band 14q32. | |||||||||||
| Case/UPN . | Diagnosis . | sCD3 . | Karyotype . | Metaphase YAC . | No. of Patients Interphase Signals . | No. Total of . | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | . | . | . | Location . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | Interphase . |
| . | . | . | . | . | . | . | . | . | . | . | Cells . |
| . | . | . | . | . | . | . | . | . | . | . | Examined . |
| T-ALL 103.3 | Myeloid/pre T-cell line | — | 46,XY,t(8; 14)(q24; q11),−9,der(12)t(12; 13)(p11; q11), −13,+2mar [10] | 14, (der14), der(8) | 4 | 11 | 79 | 4 | 2 | — | 109 |
| RPMI 8402 | T-cell line | αβ | 82∼89,XXX,add(4)(q35)×2,del(6)(q?)×2,−8, t(11; 14)(p15; q11)×2,−13×2,−15×2,−18,−22,+2-4mar [cp8] | 14, der(14), der(11) | — | — | — | — | — | — | — |
| Pre | T-ALL | +* | 46,XY,t(11; 14)(p13; q11)[14] | 14, der(14), der(11) | 5 | 63 | 32 | — | — | — | 201 |
| 258 | T-PLL | αβ | 46,XX[1]/44-45,XX,del(1)(q?),−2,add(5)(p?),−6, −7,−8,add(9)(p?),del(11)(q21),add(12)(p?),t(14; 14) (q11; q32),add(16)(q?),+mar1,+mar2×2 [cp8] | der(14+)¶, der(14q−)# | 9.5 | 54 | 30 | 5 | 1 | 0.5 | 190 |
| Bru | AT | — | 46,XY[3]/45,XY −14,der(14)t(14; 14)(q11;q32), inc[22]ρ | der(14q+)¶ | — | — | — | — | — | — | — |
| Deb | T-PLL | αβ | 46,XY[1]/42-45,XY,−2,−3,i(8)(q10),del(11)(q21),−12, inv(14)(q11q32),+3mar[cp18] | 14, inv(14)**, mar# | 4 | 77.5 | 18 | 0.5 | — | — | 249 |
| 231 | T-ALL | — | 46,XX [1]/46,XX,add(10)(q?),−14,+mar[3]/46,id,i(14)(q10)[5] | 14, add(10), mar# | 0.5 | 17 | 71 | 11 | 0.5 | — | 205 |
| Gam | AT | — | 46,XX [26]/46,XX,der(14) [6] | 14, der(14)¶ | — | — | — | — | — | — | — |
| HP-BALL | T-cell line | αβ | 89∼91,XX,t(1; 5)(q31; q34)×2,−3,−7,−8,−13, add(14)(q32)×2,−16×2,+mar1×2,+mar2×2 [cp6] | 4 × 14 | — | — | — | — | — | — | — |
| 572 | T-ALL | γδ | 46, XX,−5,add(14)(q32),+mar [20] | 2 × 14 | 7.5 | 89 | 2.5 | 1 | — | — | 200 |
| Peer | T-cell line | γδ | 86∼90,XXX,−4×2,−5,+6,del(6)(q?)×2,+7×2,−8×2, del(9)(p?)×2,+i(9)(p10)×2,−12,−13,−15,−18,+3-5 mar [cp9] | 4 × 14 | — | — | — | — | — | — | — |
| Molt13 | T-cell line | γδ | 46,XX,i(17)(q10)[10] | 2 × 14 | — | — | — | — | — | — | — |
| Molt4 | T-cell line | — | 96∼100,XXYY,+4,del(6)(q?)×2,+7,i(7)(q10)×2, +8,+9,−13,+3mar [cp6] | 4 × 14 | — | — | — | — | — | — | — |
| 639 | T-ALL/AML† | — | 84∼86,−11,del(11)(q23),−14×1∼3,+10mar,inc [20] | 3 × 14 | 3 | 29 | 61.5 | 6 | 0.5 | — | 201 |
| 957 | T-ALL | γδ | 46,XX[40]/47,XX,+8[4]∥ | 14, inv(14) | 4 | 88.5 | 7.5 | — | — | — | 200 |
| Sh | T-ALL | — | 46,XY[20] | 2 × 14 | 6.5 | 92 | 1.5 | — | — | — | 203 |
| 226 | T-ALL/AML* | — | 46,XY[18] | 2 × 14 | 9 | 89 | 1 | 1 | — | — | 173 |
| Lin | T-ALL | — | 46,XY[20] | 2 × 14 | 6.5 | 92.5 | 1 | — | — | — | 200 |
| 951 | T-ALL | αβ | 46,XX[65] | 2 × 14 | 6 | 86.5 | 5.5 | 2 | — | — | 207 |
| 872 | T-ALL | αβ | 46,XY[16] | 2 × 14 | — | — | — | — | — | — | — |
| 634 | T-ALL | — | 46,XY[21] | 14, inv(14) | — | — | — | — | — | — | — |
| 586 | T-ALL* | — ‡ | 46,XY[20] | der(14), der(10) | 6 | 93 | 1 | — | — | — | 204 |
| 282 | LGL-AL* | — | 46,XX[23] | 14, der(14), der(10) | 3 | 46.5 | 36.5 | 8 | 5 | 1 | 202 |
| Control means (n = 6) | 5.7 | 91.8 | 2.3 | 0.2 | — | — | 198 | ||||
| Control SD | 2 | 3.25 | 1 | — | — | — | — | ||||
| Abbreviation: UPN, unique patient number. | |||||||||||
| * See text for full immunophenotypic details. | |||||||||||
| † TCR αβ and γδ not assessed. | |||||||||||
| ‡ CD3 weak. | |||||||||||
| ρ Includes the analysis of mitoses containing other structural abnormalities. | ∥ Total number of metaphases examined in blood and bone marrow cultures. | ||||||||||
| ¶ Two signals observed at positions corresponding to bands 14q11 and 14q32. | |||||||||||
| # One signal observed at a position corresponding to band 14q11. | |||||||||||
| ** One signal observed at a position corresponding to band 14q32. | |||||||||||